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ttp://dx.doi.org/10.1016/j.jmoldx.2017.01.006Laboratory tests have a key role in preventing human papillomavirus (HPV)edriven carcinomas and in
guiding therapeutic interventions. An understanding of the virology, immunology, and carcinogenesis
of HPV is essential for choosing appropriate diagnostic test modalities and developing new and even
more effective cancer prevention strategies. HPV infects basal epithelial cells on multiple surfaces and
induces carcinoma primarily in the cervix and the oropharynx. HPV types are stratified as high risk or
low risk based on their carcinogenic potential. During oncogenesis, HPV interferes with cell cycle
regulation and incites DNA damage responses that thwart apoptosis and enable mutations to accu-
mulate. Such mutations are an adverse effect of innate and adaptive antiviral immune responses that
up-regulate DNA-editing enzymes, with natural selection of cells having a chromosomally integrated
viral genome lacking expression of viral proteins targeted by the immune system. Infected cancers share
a similar mutation signature, reflecting the effect of apolipoprotein B mRNA-editing catalytic poly-
peptide enzyme DNA-editing enzymes. It is feasible that genomic tests for characteristic mutations or
methylation signatures, along with tests for dysregulated HPV gene expression, add value in predicting
behavior of premalignant lesions. Furthermore, these tumor markers in cell-free DNA of plasma or body
fluids may one day assist in early detection or monitoring cancer burden during treatment. (J Mol Diagn
2017, 19: 366e377; http://dx.doi.org/10.1016/j.jmoldx.2017.01.006)Supported by NIH grant UL1 TR001111 (M.L.G.), the Lineberger
Comprehensive Cancer Center, and the University of North Carolina at
Chapel Hill Department of Pathology and Laboratory Medicine.
Disclosures: None declared.Microbial Influence on Human Malignancies
Over a century ago, the pathologist Peyton Rous showed
that cell-free tumor extracts containing the Rous sarcoma
virus were able to transmit tumors between chickens.
Several years later, he identified a papillomavirus as the
cause of benign warts in rabbits. Despite his extraordinary
work, microbe-mediated oncogenesis was considered a
scientific curiosity until Epstein and Barr’s 1967 identifi-
cation of viral particles in human Burkitt lymphoma.1 Since
the discovery of the Epstein-Barr virus, six more virusesstigative Pathology and the Association for Mhave been identified as the etiological agents of human
malignancies, including hepatitis B virus, hepatitis C virus,
human T-lymphotropic virus-1, human herpevirus 8, merkel
cell polyomavirus, and human papillomavirus (HPV).1
Current estimates link a viral etiology to 10% to 15% of
all human malignancies.2 In addition, the bacteriumolecular Pathology. Published by Elsevier Inc. All rights reserved.
HPV Carcinogenesis and GenomicsHelicobacter pylori and the parasites Clonorchis sinensis
and Schistosoma haemotobium are associated with human
malignancies.3
Despite significant progress, much remains to be learned
about the mechanism by which microbes contribute to
malignant transformation. In some instances, microbial-
derived factors interact directly with specific cellular path-
ways to increase cellular proliferation, inhibit apoptosis,
and induce accumulation of mutations within infected cells.
Activation of the immune system can cause bystander
damage to DNA through nonspecific toxic mediators, such
as reactive oxygen species, and direct mutagenesis via
up-regulation of DNA-editing enzymes such as apolipo-
protein B mRNA-editing catalytic polypeptide enzymes
(APOBECs).1,4 Recent large-scale genome studies showed
the effects of this family of enzymes by virtue of distinct
mutation signatures in microbe-related cancers including
HPVþ neoplasms.5
In this review article, we examine recent updates in our
understanding of HPV carcinogenesis and the implications
of this knowledge on current and future diagnostic strategies
to improve early detection and targeted interventions.HPV Virology and Type Prevalence
HPV is a nonenveloped circular double-stranded DNA
(dsDNA) virus in the papillomaviridae family that infects
basal epithelial cells in the epidermis and mucosae.6 There
are now five genera, 49 species, and 202 HPV types
recognized by the International Human Papillomavirus
Reference Center.6 Genera exhibit <60% sequence
homology in the L1 gene encoding the major capsid protein,
and are designated a, b, g, m, and .6 Members of the a
genus infect the genital mucosa, whereas members of all
five genera infect the oral mucosa and skin.7 Species exhibit
60% to 70% homology, and types exhibit >90%
homology.6
High-risk HPV types typically refer to those types having
a causal association with cervical cancer. Overlapping
subsets of these high-risk HPV types are causally related to
other lower anogenital tract cancers and head and neck
cancers. The International Agency for Research on Cancer
working group classifies HPV types as carcinogenic to
humans, probably carcinogenic, possibly carcinogenic, or
low risk. Commercial molecular tests described below can
identify each high-risk type, including the two most onco-
genic types, HPV 16 and 18.8 Massive parallel sequencing
is capable of distinguishing all HPV types, and emerging
data suggest prognostic impact of HPV type in oropharyn-
geal carcinomas.9e11
A meta-analysis of 423 published studies reveals the
percentage of each high-risk type in cervical carcinoma and
premalignant lesions.7 Some geographic variability in type
prevalence is seen both in cervical and in head and neck
cancers. For example, in North America, HPV is identifiedThe Journal of Molecular Diagnostics - jmd.amjpathol.orgin 60%, 13%, and 19% of carcinomas arising in the
oropharynx, oral cavity, and larynx, respectively, and global
rates are similar; HPV16 is the most common type at all
geographic locations.12 The next most common types vary
by geographic location and anatomical site (Table 1).
Notable variations include identification of HPV18 in 25%
of HPVþ carcinomas in the oral cavity worldwide versus
7% in North America and up to 40% in Asia.12 Furthermore,
HPV types associated with laryngeal cancer in Central and
South America differ from other geographic locations with
higher rates of HPV58, 45, 51, 59, and 66 and minimal
HPV18.12 Laboratorians should note these geographic dif-
ferences and choose diagnostic test strategies that are suited
to their patient population.HPV Gene Expression and Its Effects on Host
Cells
HPV infection requires abrasion of the surface epithelium
with exposure of the basement membrane, enabling viral
binding to exposed heparan sulfate proteoglycans.13 Furin
bound to the basement membrane cleaves L2 on the viral
capsid, exposing the major viral capsid protein L1, which is
the target of prophylactic vaccines.13,14 L1 binds to an
unknown receptor on adjacent basal epithelial cells, result-
ing in viral entry via endocytosis in the first 2 to 4 hours,
uncoating in the late endosome (8 to 12 hours), and release
of viral dsDNA complexed with L2 into the cytosol.13 Viral
DNA enters the nucleus within 24 hours, with transcription
of six early genes: E1, 2, 4, 5, 6, and 7.13 E1 and E2 are
required for viral episome replication to yield approximately
100 viral genomes per cell. Multiple copies of the viral
genome facilitate localization of HPV in tissue sections by
in situ hybridization with probes targeting viral DNA.15 E2
also tethers viral DNA to the human genome with a predi-
lection for fragile sites.16,17 E5 is a membrane protein that
activates the epidermal growth factor receptor signaling
pathway, leading to cell proliferation.17 Simultaneously,
expression of E7 inhibits the retinoblastoma protein, RB1,
leading to activation of elongation factor 2, promoting S
phase and viral and cellular DNA replication.17 RB1 inhi-
bition up-regulates CDKN2A/p16, permitting us to exploit
p16 immunohistochemistry as a surrogate marker for HPV
infection.18 Meanwhile, expression of E6 inhibits TP53 and
BAK, allowing for mutation accumulation in infected cells
that are now restricted in their ability to induce apoptosis in
response to DNA damage.17 E6 also induces the transcrip-
tion of methyltransferases and methylases, resulting in
epigenetic-mediated changes in gene expression that pro-
mote carcinogenesis. E6 and E7 mRNAs are targeted by in
situ hybridization probes to localize HPV infection to spe-
cific cells in biopsy specimens.19
As infected epithelial cells mature, E4 binds to cytoker-
atins and helps orchestrate viral capsid assembly and
intracellular trafficking of viral components.14 The effects of367
Table 1 HPV Types in Infected Cervical Carcinoma and in Head and Neck Carcinoma
HPV type Prevalence globally or (in North America) [in Central and South America] {in Asia}*
IARC group Viral type Cervix Oropharynx Oral cavity Larynx Variousy
Any type w100 46 (60) [15] 24 (13) [33] 22 (19) [32] Low
1: High-risk carcinogenic 16 56 88 (91) [99] 62 (80) [70] 61 (68) [78]
18 14 <1.5 25% (7) [23]{40} 7 (15) [20]
45 5 [10]
33 4 1.5 <1
58 4 <1.5 [20]
31 4 <4
52 3
35 2 <1.5
39 1 Low
59 1
51 1 <1 [10]
56 1
2A: probably carcinogenic 68 0.5
2B: possibly carcinogenic 53 0.5 Low
73 0.5 Low
66 <0.5 [10] Low
67 <0.5
26 <0.5
30 <0.5
69 <0.5 Low
70 <0.5
82 <0.5
85 <0.5
34/64 <0.5
a Group: low risk 6 <0.5 <1.5 <4 6
11 <0.5 <4 <1
8 Low
13 Low
32 Low
b Group: low risk 38 <4
*Data are given as percentage.
yVarious head and neck carcinomas rarely harbor the types noted; coinfections account for >100% totals across types.
HPV, human papillomavirus; IARC, International Agency for Research on Cancer.
Leal and GulleyE4 are likely responsible for the diagnostic perinuclear halo
observed in HPV-infected epithelial cells known as koilo-
cytes.14 With further cell maturation, the capsid proteins L1
and L2 are produced and inserted into newly formed viral
capsids that exit the cell via exocytosis.13
There is no lytic phase of viral infection; instead, new
virions enter adjacent basal epithelial cells via endocytosis
and do so irrespective of prior cell infection.13 This can
expose the same cell to multiple waves of infection.13
Although genomic analyses have identified multiple viral
types in HPVþ clonal neoplasms,20 definitive proof of
coinfection at the single-cell level is lacking, and published
studies using microdissection and in situ hybridization
localize viral types to distinct cellular populations in coin-
fected specimens.21 HPV coinfection is present in 12% of
cervical carcinomas and up to 39% of precursor lesions, and
in 0.3%, 2%, and 1% of carcinomas in the oropharynx, oral
cavity, and larynx, respectively.7,12 In addition, certain HPV
combinations occur more often than by chance alone368(HPV11-HPV53, HPV31-HPV33, and HPV34-HPV42).22
The burden of HPV16 viral DNA in precursor lesions cor-
relates with a higher risk of cancer progression23 and the
same is likely true for other high-risk HPV types.HPV Activation of the Innate Immune Response
HPV infection poorly elicits innate and adaptive immune
responses.24 Traumatic injury to epithelial cells during
initial infection releases danger-associated molecular pat-
terns that activate pattern recognition receptors on epithelial
cells and leukocytes, leading to inflammation.25 After
healing, the virus spreads with minimal danger-associated
molecular pattern production and inflammation.14
Although the cytoplasm contains innate dsDNA sensors
(eg, POLR, IFI16, MB21D1, TMEM173, DDX41, ZBP1),
and endosomes harbor Toll-like receptors (Toll-like receptor
9), HPV dsDNA seems to be unrecognizable.26 Instead,jmd.amjpathol.org - The Journal of Molecular Diagnostics
HPV Carcinogenesis and GenomicsHPV dsDNA may be either restricted to the nucleus, sur-
rounded by viral capsid, or complexed to L2 proteins,
making it unavailable for innate immune recognition.13 In
addition, the CGAS-STING complex is inhibited and
expression of Toll-like receptor 9 is down-regulated by viral
proteins.24 In the meantime, the adaptive immune response
is impeded by scant inflammation, infection restricted to
epithelial cells that lie outside the basement membrane, and
relatively low viral protein expression, all of which limits
the utility of serological assays for viral diagnosis.24
Serology is also insufficient for viral typing and poorly
responsive to clearance of high-risk HPV from the body,
whereas tests for viral nucleic acid are more informative of
infection status.27 Although viremia is lacking for intra-
epithelial lesions, detection of HPV DNA in plasma or
serum is considered a promising biomarker for HPVþ car-
cinomas.28,29 It seems that invasive tumor cells quickly turn
over, releasing genomic and viral DNA into the blood.27,30
Histopathological diagnosis of HPVþ precursor lesions
relies primarily on architectural distortion of the epithelium.
Increased epithelial permeability is thought to expose
epithelial cells and resident leukocytes to commensal bacteria
and to proinflammatory molecules, resulting in inflammation
and bystander damage to HPV-infected cells.31 Viral uptake
by infiltrating leukocytes activates intracellular dsDNA sen-
sors, type 1 interferon production, antigen presentation, and
activation of adaptive immunity.14,24 Autocrine and paracrine
effects of type 1 interferon a/b on infected epithelial cells up-
regulates >300 genes that work in concert to degrade viral
nucleic acid, inhibit protein translation, promote proteasomal
protein degradation, inhibit viral exocytosis, and mutate viral
genomes via APOBEC enzymes.24,26Antiviral APOBEC Activity and Mutation
Signatures Identifiable by Genomic Sequencing
APOBEC enzymes deaminate cytosine to uracil on single-
stranded DNA molecules, resulting in single base sub-
stitutions.32 The best characterized member of the APOBEC
family is activation-induced cytidine deaminase, which
mediates B-cell somatic hypermutation and has known off-
target mutagenicity (eg, in MYC and BCL6).32,33 Interferon
b up-regulates the expression of at least two APOBEC en-
zymes (3A and 3G) that induce mutations in single-stranded
DNA (both human and viral).33,34 Single-stranded DNA is
prevalent after viral-driven cellular proliferation that leads to
reagent exhaustion and exposure of stalled DNA replication
forks and transcription bubbles.34e36 More important, most
transcribed genes in infected cells are involved in cellular
proliferation, establishing a dangerous situation in which the
single-stranded DNA exposed to APOBEC mutagenesis is
enriched for proto-oncogenes.32,37 A multistep model of
HPV oncogenesis is illustrated in Figure 1.
Mutation signatures are unique patterns of DNA damage
that occur because of the action of a specific mutagen andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgsubsequent host DNA repair response.38 Even when the
mutagen is no longer present, mutation signatures persist
and reflect the mutagen’s contribution to hit-and-run events
culminating in cancer.38 Mutation signatures are formidable
in their capacity to provide mechanistic information on how
a particular mutation might have occurred.
Virus-associated cancers, including HPV-infected malig-
nancies, exhibit an APOBEC mutation signature character-
ized by deamination of cytosine to uracil in single-stranded
DNA. This results in a C>T conversion if DNA replication
occurs before base excision repair, or C>G and C>A con-
versions if repair occurs before DNA replication.5,37,38
Recent analysis of head and neck squamous cell carcinoma
identified mutation signatures mechanistically consistent
with aging, smoking, UV light, and APOBEC activity.4 The
latter was linked to HPV presence in cancers of oropharyn-
geal origin.12 Cervical cancer is nearly universally HPV
positive, and mutation signatures point to age and interferon-
stimulated APOBEC activity as the main mechanisms of
oncogenesis.4 The power of genomic assays to trace back to
causative mutagens cannot be underestimated as a tool for
epidemiology and for devising cancer prevention strategies.
Mutation analyses have the potential to identify action-
able mutations that predict treatment response or that confer
prognostic information.39 However, given that surgical
excision and radiation therapy typically obviate the need for
targeted therapy, the clinical utility of sequencing HPVþ
carcinomas is limited. As the cost and convenience of per-
forming next-generation sequencing in clinical laboratories
continue to improve, it may become routine to sequence
carcinomas at the time of diagnosis to identify patient-
specific tumor mutations by which to track tumor burden
and to predict recurrence, using either repeat biopsies or
serial plasma DNA analysis. Likewise, it may become
practical to sequence cervical precursor lesions to predict
their aggressiveness or to devise customized surveillance
plans. Given that current data are lacking, future research
efforts should focus on identifying the sensitivity and
specificity of genomic mutations to identify precursor le-
sions at high risk of progression to cancer.
Common recurrent mutations in cervical cancer and
HPVþ head and neck carcinoma are listed in Figure 1.40,41
The genes that are frequently mutated in HPVþ carcinomas
are involved in cell signaling, cell growth, histone modifi-
cation, chromatin remodeling, and DNA repair.40,42 The
most common mutations in HPVþ carcinomas activate the
phosphatidylinositol 3-kinase/AKT/mammalian target of
rapamycin cell signaling pathway to promote cell
growth.40,42 Some variants in the histocompatibility com-
plex and in B2M involved in antigen presentation, likely
thwart immune responses to viral epitopes and to tumor-
derived neoantigens.40,42
Incorporating viral targets into next-generation
sequencing panels could streamline the process of identi-
fying viral and somatic tumor markers to be used to monitor
tumor burden and to demonstrate efficacy of therapy.39369
Figure 1 The pathobiology of HPV carcino-
genesis and clinical assays to characterize disease
status. A: Molecular tests that identify viral DNA
include in situ hybridization (ISH), the Qiagen
Hybrid Capture 2, Roche Cobas, and Hologic Cer-
vista HPV assays. B: E6/E7 viral RNA is targeted by
ISH and the Hologic Aptima HPV assay. C: The HPV
surrogate CDKN2A/p16 is targeted by immunohis-
tochemistry. D: The risk of progression of precursor
lesions can be detected by promotor methylation
panels. E: Druggable mutations in HPVþ tumors are
detected by massive parallel sequencing and RNA
sequencing. F: Noninvasive measurements of
tumor burden in plasma samples can be performed
with massive parallel sequencing of tumor-specific
human variants and by measuring viral load by
real-time quantitative PCR. Recurrent mutations in
HPVþ cervical carcinomas are identified in genes
encoding proteins involved in cell signaling
[PIK3CA (25%), APC (10%), NOTCH1 (10%), PTEN
(8%)], histone modification [MLL3 (20%), MLL2
(18%), EP300 (10%)], transcription regulation
[NFE2L2 (15%), CREBBP (12%) SPEN (12%)],
chromatin remodeling [ARID1A (15%), ATRX
(8%)], cell cycle control [CDK12 (10%)], DNA
repair [TP53 (5%)], and the immune response
[HLA-B (9%)]. Recurrent mutations in HPVþ head
and neck carcinoma are identified in genes
encoding proteins involved in cell signaling
[PIK3CA (56%), FGFR3 (11%)], transcription
regulation [E2F1 (19%)], and the immune
response [TRAF3 (22%), HLA-B (11%)]. APOBEC,
apolipoprotein B mRNA-editing catalytic peptide;
Bak, Bcl2 homologous antagonist killer; dsDNA,
double-stranded DNA; E2F, elongation factor 2;
EGFR, epidermal growth factor receptor;
IL, intraepithelial lesion; p53, tumor protein 53
(TP53); qPCR, real-time quantitative PCR; Rb1,
retinoblastoma protein; ssDNA, single-stranded
DNA.
Leal and GulleyAdaptive Immunity and Selection of Cells with
Integrated Viral Genomes
The major components of the adaptive immune response to
HPV include a CD8þ cytotoxic T-cell response to E2 and
B-cellemediated production of antibodies to E2, E6, E7, L2,
and the major capsid protein L1.24 Antibodies to L1 inhibit
virions from binding to the unidentified receptor on basal
epithelial cells,13,14 and thus current vaccines aim to induceL1
antibodies to levels 10-fold over the level seen with natural
infection to prevent new infections.14,24 CD8þ T-cell responses
to HPV antigens kill infected epithelial cells that synthesize
enough target viral protein (eg, E2, E6) for intracellular pro-
cessing and major histocompatibility complex class I antigen
presentation.14,24 This is the likely mechanism for viral clear-
ance and lesion regression observed in some patients.14370Integration of the viral genome into host chromosomal
DNA can disrupt viral gene expression patterns, leading to
lack of immunogenic viral proteins and escape from adaptive
immune control.14,20 Integration events occur at a rate of
approximately 36 per cervical carcinoma clone, or 1 to 16 per
head and neck carcinoma clone.43,44 HPV DNA in situ hy-
bridization staining patterns can distinguish episomal (diffuse
nuclear) versus integrated viral genomes (punctate nuclear).15
Massive parallel sequencing can also be used to identify HPV
insertion sites into the host genome.45 The breakpoint in the
circular HPV16 genome occurs most frequently in
E1>L1>L2>E2 and the same pattern is likely true for other
high-risk HPV types.43 E2 disruption favors oncogenesis
because E2 negatively regulates E6 and E7 transcription, so
E2 disruption increases expression of the primary viral drivers
of proliferation and cell survival to facilitate mutationjmd.amjpathol.org - The Journal of Molecular Diagnostics
HPV Carcinogenesis and Genomicsaccumulation.13,36 In addition, diminished E2 expression
promotes evasion from cytotoxic T cells.36
Recent viral transcriptome analyses in HPVþ tumors
confirm low or absent E2 expression in most HPVþ tumors
and near universal high level expression of E7.20 A subset
of tumors overexpress E4 and E5, likely representing
replication of nonintegrated virus.20 There are variable
levels of intact functional E6, although more commonly
tumors produce truncated E6 transcripts encoding ques-
tionably functional, nonimmunogenic E6 protein that eludes
the immune system while also thwarting apoptosis. In the
meantime, cell growth is driven by E5 and E7, and antigen
presentation is thwarted in host cells via E7-mediated in-
hibition of TAP1 required to load peptides onto major his-
tocompatibility complex 1 molecules.24,36Viral Integration into Host Chromosomes
Affects Host Gene Structure and Expression
Genomic sequencing reveals that viral integration regions
favor chromosomal fragile sites, so named because they are
prone to breakage, rearrangement, or gene amplifica-
tion.16,43,44 These fragile sites often contain large genes
(>800 kb) requiring prolonged time for transcription,46
raising the possibility that under conditions of proliferative
stress, gene transcription may not be completed before S
phase, triggering the DNA damage response during G2.
32,46
In the context of HPV infection, E7-driven cellular prolif-
eration increases proliferative stress, and viral episomes
tethered to chromatin take advantage of the DNA damage
response to replicate viral genomes during G2.
16,43,47 Viral
replication in close proximity to a fragile site may increase
risk of integration. Of HPV integration sites, 42% occur
within 10 kb of a human gene copy number variant.16,20
Some HPV integration events occur at recurrent
microhomology-dependent hot spots, and these hot spots are
often in genes with a plausible role in tumorigenesis, such as
the DNA repair factor FHIT (9% of integration events), the
cell signaling protein DLG2 (5%), the cell-cell interacting
protein SEMA3D (5%), and transcriptional regulators:
POU5F1B (10%), KLF12 (8%), KLF5 (7%), and HMGA2
(8%).43 Alternate genes without a known link to tumori-
genesis include the low-density lipoprotein receptor LRP1B
(6%) and collagen-hydroxylating enzyme LEPREL1 (5%).
In cancers other than cervical, HPV integration hot spots are
reported in genes involved in cell signaling (ERBB2/HER2),
DNA repair (RAD51B), DNA methylation (MLL4), and cell-
cell interaction (FN1), and in long noncoding RNAs
involved in MYC regulation (PVT1, LOC727677).20
Transcriptome analyses of HPVþ versus HPV head and
neck cancer identified 1897 genes with greater than twofold
change and 597 genes with greater than fourfold change in
transcript levels.20 Indeed, expression patterns in HPVþ
head and neck cancer were more similar to HPVþ cervical
carcinoma than to HPV head and neck cancer,The Journal of Molecular Diagnostics - jmd.amjpathol.orgemphasizing the large and consistent impact of HPV and
virtually eliminating the possibility that the virus is an
innocent bystander in carcinogenesis. The most up-
regulated gene in HPVþ tumors is CDKN2A/p16 (10.6-
fold; bolstering evidence for its use as an immunohisto-
chemical surrogate for HPV infection), followed by genes
involved in transcriptional regulation (RANBP17, HLF,
MYB, POU2AF1, MYCN ), cell proliferation (CDKN2C ),
and immune activation (CD79A, TNFRSF17).20 Down-
regulated genes include transcription factors (FOXL2,
HMGA2, HOXC13) and cell signaling factors (ROS1,
FSTL3). The net effect is to impede cell differentiation while
promoting proliferation and immune evasion. RNA
sequencing is a powerful new tool to simultaneously profile
dysregulated human genes and viral transcripts as well as to
detect somatic mutation in expressed genes.48
Epigenetic Modifications Reflect Viral Presence
and Characterize High-Risk Precursor Lesions
HPV infection induces epigenetic changes in viral DNA as
well as in the host genome.49 Viral E6 and E7 both up-
regulate the enzyme DNA methyltransferase 1, resulting in
methylation of multiple genomic sites.49 In addition, HPV
infection up-regulates DNA methyltransferase and histone
lysine demethylases, which function in concert to alter gene
transcription and promote carcinogenesis.49 For a compre-
hensive review of epigenetic changes associated with HPV,
refer to Steenbergen et al.49 In brief, methylation of E2
binding sites on the HPV genome interferes with E2-
mediated inhibition of E6 and E7 expression.49 Molecular
assays examining selected methylated promoters (eg,
RUBCNL, JAM3, ANKRD18CP, TERT ) may add value
beyond high-risk HPV presence to identify lesions with
cervical intraepithelial neoplasia 2.19 In head and neck
carcinoma, an HPV-related methylation signature is
prognostic.50
Vaccines and Immunotherapy
Understanding the pathobiology of HPV carcinogenesis
has led to novel interventions to limit viral infection in
exposed patients. Efficacious prophylactic vaccines work
by eliciting protective neutralizing antibodies to the L1
protein of selected HPV types, and bivalent, quadrivalent,
and nine-valent vaccines are available.51 The nine-valent
vaccine (Gardasil-9) blocks HPV types responsible for
90% of cervical carcinomas. Vaccination will likely help
prevent HPVþ head and neck carcinomas as well.52
Despite their benefits, prophylactic vaccines are underu-
tilized, do not target all pertinent HPV types, and lack
efficacy against preestablished infections.53 Several
novel approaches to cancer therapy target viral E6 and
E7 proteins, or PDL1 inhibition to promote T-cell
activity.14,20,54,55371
Table 2 Laboratory Tests for Human PapillomaviruseRelated Neoplasia
Test
FDA
approved Technology Advantages Disadvantages
CDKN2A/p16
immunohistochemistry
No Targeted antibody binds
CDKN2A/p16, tagged
secondary antibody,
colorimetric
Rapid, inexpensive, readily
interpreted by pathologists
using practice guidelines,
localizes an effect of
oncogenic HPV to
neoplastic cells
Does not detect virus, rather
detects a non-specific
effect of oncogenic virus,
no genotyping, subjective
interpretation
E6/E7 RNA in situ
hybridization
No Tagged DNA probes
complementary to
oncogenic E6/E7 RNA,
colorimetric
Identifies viral transcripts
not a surrogate marker;
rapid, inexpensive, localize
to neoplastic cells
No genotyping, varying RNA
integrity, subjective
interpretation
HPV DNA in situ
hybridization
No Cocktail of tagged DNA
probes complementary to
HPV DNA, colorimetric
May distinguish episomes
from integrated virus, can
genotype certain HPV
types, rapid, inexpensive,
localize to neoplastic cells
Less analytic sensitivity than
above tests, potential
cross-reactivity with
low-risk HPV, subjective
interpretation
qPCR or RT-qPCR No Extract nucleic acid, amplify
conserved or type-specific
gene segments, measure
products during
amplification compared to
standards and endogenous
control DNA/RNA
Sensitive detection of
conserved regions across
all HPV types, or of
type-specific regions,
quantify viral load in fixed
tissue, cells, or body fluids
Difficult to distinguish virus
in neoplastic versus
non-neoplastic cells or
extracellular
Qiagen Digene HC2
High-Risk HPV
DNA assay
Yes RNA probe hybridizes to viral
DNA, primary antibody
captures DNA-RNA hybrids,
secondary labeled antibody
detects DNA-RNA hybrids,
chemiluminescent signal
Detects 13 high-risk HPV
types (16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59,
and 68)
No genotyping, no
control for specimen
adequacy, large specimen
volume, potential
cross-hybridization with
low-risk types
Hologic Cervista HPV
HR assay
Yes Partially overlapping probes
bind viral DNA, enzyme
cleaves viral probe and
product hybridizes to
labeled probe, enzyme
cleaves that probe,
fluorescent signal
Detects 14 high-risk HPV
types (same 13 as Qiagen
HC2 plus type 66)
Hologic Cervista HPV
16/18
Yes Same as above but probes
target HPV16 or HPV18 and
cleavage products bind to
differentially labeled
probes
Genotypes HPV16 and 18
Roche Cobas HPV test Yes Multiplex real-time PCR to
amplify HPV L1 gene
segment with labeled
TaqMan probes with
specificity for HPV16 only,
HPV18 only, or 12 other
high-risk HPV types
Primary screening for cervical
neoplasia, detects 14
high-risk HPV types (same
13 as HC2 plus type 66),
genotypes HPV16 and 18
Hologic Aptima HPV Yes Probes on magnetic particles
hybridize to E6/E7 mRNA,
reverse transcribed to
cDNA, T7 RNA polymerase
transcription for
amplification,
chemiluminescence
High specificity for
oncogenic viral types
(table continues)
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Table 2 (continued )
Test
FDA
approved Technology Advantages Disadvantages
Hologic Aptima HPV
16 18/45
Yes Same as above except
oligomer targets
unspecified viral mRNA,
chemiluminescent probes
bind HPV16, 18, and 45,
rapid light emission
kinetics denote HPV16,
whereas slow kinetics
identify HPV18 or 45
Genotypes HPV16 and HPV18
and/or 45
Massive parallel
sequencing
No Enrich for HPV genome and
other gene regions of
interest, add barcodes
and adapters before
sequencing, record signal
as nucleotides are added
during strand replication,
call each nucleotide
position, align reads to
reference sequence, view
aligned reads, interpret for
viral presence and/or type
and other sequence
variants
Theoretically detects all HPV
types; streamlined
incorporation into tumor
mutation sequencing
panels
Expensive, long turn-around
time, complex
interpretation
Methylation panel No Bisulfite treatment of DNA
followed by methylation-
specific PCR or sequencing
of recurrently methylated
genes in high-risk
precursor lesions of the
cervix
Excellent specificity for
precursor lesions likely to
progress
Technically challenging,
complex interpretation
FDA, Federal Drug Administration; HC2, Hybrid Capture II; HPV, human papillomavirus; qPCR, real-time quantitative PCR; RT-qPCR, quantitative RT-PCR.
HPV Carcinogenesis and GenomicsEarly Diagnosis of Pertinent Cervical Lesions and
Triage of Patients with Atypical Squamous Cells
Prevention of cervical carcinoma is the primary goal of
screening programs that continue to be refined as new evi-
dence emerges. Current US guidelines for screening are
summarized by the American College of Obstetricians and
Gynecologists (http://www.acog.org/Womens-Health/Cervical-
Cancer-Screening, last accessed January 5, 2017). Briefly,
cytology alone every 3 years is recommended for women from
age 21 to 29 years, because this is an age range in which HPV
infection and clearance is common, rendering detection of HPV
less informative.24,56 Immune suppression increases viral
persistence, warranting different screening strategies.56 After the
age of 29 years, HPV detection suggests persistent infection.
Thus, women aged 30 to 65 years have the additional option for
cotesting (cytology plus a high-risk HPV assay) every 5 years.
Recent Federal Drug Administration (FDA) approval of a
standalone high-risk HPV molecular assay (cobas HPV test
from Roche) every 3 years is also an option for women >25
years.57 Women with pathology of moderate-to-high grade
cervical intraepithelial neoplasia (2 or 3) should receiveThe Journal of Molecular Diagnostics - jmd.amjpathol.orgcontinued screening for at least 20 years using cotesting, even
after the age of 65 years.56
Another role for high-risk HPV testing is to stratify
patients with a cervical cytology diagnosis of atypical squa-
mous cells of undetermined significance into those at low risk
versus the 40% at higher risk for cervical neoplasia in whom
colposcopy is indicated for better endocervical sam-
pling.56,58,59 By detecting 96% of cervical intraepithelial
neoplasia 3 or cancer, high-risk HPV screening limited col-
poscopy to 56% of women with atypical squamous cells of
undetermined significance, saving costs and anguish while
effectively identifying women who need intervention.58HPV Laboratory Tests Validated for Use in
Cervical Screening Programs
Only six HPV molecular tests are currently FDA approved
for screening programs in cervical samplings8 (Table 2).
Use of noneFDA-approved screening tests is discouraged
because of many complex analytic and clinical aspects that
cannot be validated outside of large clinical trials, and373
Leal and Gulleybecause of the medical and economic impact of suboptimal
assay performance.
The Qiagen Digene HC2 high-risk HPV test detects 13
HPV types using probe hybridization to viral DNA in a
96-well microplate format.60 The assay is FDA approved for
atypical squamous cells of undetermined significance strat-
ification and screening in combination with cytology in
women age 30 years and over.
The Hologic Cervista HPVHR assay detects 14 HPV types,
including the 13 detected by the Hybrid Capture 2 (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) as well as type 66
using Invader probe technology.61 The assay is FDA approved
for essentially the same indications as the Qiagen Digene HC2
test. A separate genotyping assay, Cervista HPV 16/18 assay,
specifically detects types 16 and 18 and is performed in reflex
to a positive Cervista HPV HR assay to further risk stratify
women referred for colposcopy and follow-up.62
The Roche cobas HPV test relies on real-time PCR to
detect the same 14 high-risk HPV types and optionally to
individually identify types HPV16 and HPV18.63 The test is
FDA approved for essentially the same indications as the
Hologic Cervista assays and is additionally approved as a
standalone primary screening tool for cervical neoplasia in
women aged 25 to 64 years.63,64
The Hologic Aptima HPV assay uses transcription-
mediated amplification of viral E6/E7 mRNA transcripts
to detect HPV with oncogenic potential, and is capable of
detecting the same 14 high-risk HPV types.65,66 The assay is
FDA approved for essentially the same indications as the
Qiagen Digene HC2 test. A separate test, the Hologic
Aptima 16 18/45 assay, specifically identifies these three
common high-risk HPV types to further risk stratify women
referred for colposcopy and follow-up.67HPV Status in Oropharyngeal Carcinoma Affects
Prognosis
There is no currently recommended screening strategy to
identify patients at risk for developing HPVþ head and neck
carcinoma. However, oropharyngeal cancer has increased by
>50% in the past several decades, driven in part by changing
patterns in sexual behavior, particularly oral sex.68e71 Males
are more often affected and are usually younger non-smokers
from a higher socioeconomic status than HPV head and
neck cancer patients.70 HPVþ oropharyngeal cancer is more
sensitive to chemoradiation and carries a better prognosis;
however, a subset develop locoregional recurrence or distant
metastases, resulting in clinician reluctance to deescalate
treatment intensity.72 Smoking history imparts a worse
prognosis in affected cancer patients.12,73e75 However,
HPV16 appears to confer a better prognosis than other HPV
types,11 and studies are underway to evaluate how HPV
typing and/or genomic tests could help stratify risk of pro-
gression to cancer, and in those who already have cancer to
predict outcome in response to particular treatment regimens.374Analysis of cell-free tumor DNA in blood or saliva may help
identify metastasis or local tumor recurrence.27,28Histochemical Methods for HPV Detection and
Viral Typing on Paraffin-Embedded Tissue
Multiple approaches are available to detect and type HPV in
tumor tissue. Although up-regulated in many tumors,
immunohistochemistry targeting the host protein CDKN2A/
p16 is a sensitive and specific surrogate marker for inte-
grated HPV when positivity is interpreted as >70% of
malignant epithelial cells.18,20,76e78 Draft guidance from the
College of American Pathologists recommends p16 immu-
nohistochemistry as the first-line test to support manage-
ment decisions in oropharyngeal cancer patients, and
National Comprehensive Cancer Network guidelines sup-
port this strategy.79 Unlike oropharyngeal carcinoma, other
carcinomas of the head and neck (oral cavity, larynx,
hypopharynx, nasopharynx, sinonasal) harbor HPV less
frequently, and limited data suggest there may not be
HPV-related prognostic differences. It remains controversial
whether p16 immunostain is more informative than HPV
status for response to particular therapy for oropharyngeal
cancer, and clinical trials continue to gather evidence sup-
porting best practices. In the lower anogenital tract, p16
immunostain may be helpful to distinguish HPV-related
squamous intraepithelial neoplasia from mimics (atrophy,
squamous metaplasia, or tangential cuts).18 Testing for HPV
and Epstein-Barr virus in squamous carcinoma of unknown
primary can assist in determining the site of origin and in
weighing radiotherapy options.79
Several tests are available to directly detect HPV or its
gene products in paraffin-embedded tissue, including HPV
E6/E7 mRNA in situ hybridization, HPV DNA in situ hy-
bridization, E6/E7 immunohistochemistry, HPV E6/E7 RT-
PCR, or HPV DNA Q-PCR.19 Because HPV PCR does not
localize viral DNA to cells of interest, this test method is
best used in reflex to a positive morphology-based assay,
such as p16 immunostain. HPV DNA in situ hybridization is
limited by probe designs that typically cannot detect all
pertinent high-risk types but when positive can help reveal
episomal versus integrated staining patterns. Histochemical
tests for E6 and E7 mRNA also perform well for localizing
potentially oncogenic HPV because overexpression is
characteristic of integrated (tumor-related) virus,65,66 and
parallel control probes help ensure that RNA is adequately
preserved in the tissue. There is near universal high level E7
expression in HPVþ tumors.15,20 In contrast, E6 is often
truncated and nonfunctional with variable expression
undermining its diagnostic utility.20
HPV genotyping typically relies on primers, probes, or
sequencing of type-specific sequences in the L1 gene or its
RNA transcript.6,8 Even among the high-risk types, data
suggest that HPV typing in cervical precursor lesions adds
value in predicting risk of progression.77,78 Injmd.amjpathol.org - The Journal of Molecular Diagnostics
HPV Carcinogenesis and Genomicsoropharyngeal cancer, HPV16 seems to carry a better
prognosis than the other high-risk types, indicating a po-
tential future role for genotyping in clinical decision mak-
ing.11 HPV typing is feasible in paraffin-embedded tissue
specimens.9,45,80
Progress in Developing Genomic Tests for HPV-
Related Neoplasia
There is interest in using massive parallel sequencing to
simultaneously identify virus, assess viral types and addi-
tional viral genomic variants, and detect relevant human
gene mutations in tissue, cytology, or body fluid samples.39
Genomic methods have recently been described.9,10,45,80
Cell-free DNA assays for HPV DNA in plasma show
promise as a noninvasive measure of HPVþ carcinoma
burden, and work is underway to evaluate this approach to
monitor treatment efficacy, to identify recurrence, and to
enhance early cancer detection.27,30 A combinatorial
approach is envisioned in which plasma is analyzed for viral
DNA and for mutations common in carcinoma (eg, in
PIK3CA).41 Sequencing panels permit broad and agnostic
pathogen detection alongside human genomic characteriza-
tion that seem important for exploring synergistic mecha-
nisms of carcinogenesis involving infections (viruses,
bacteria, fungi, parasites), host immune response poly-
morphisms, DNA damage markers of prior mutagen/
microbe exposure, and DNA repair defects.4 This ambitious
work is currently in the experimental phase but holds great
promise to transform laboratory diagnostics.
Summary
HPV-driven carcinogenesis imposes a great burden on
human health. The interplay between viral propagation, the
immune response, and genomic damage is multifaceted,
and large-scale genomic studies are revealing fascinating
insights into how a virus with a small eight-protein
encoding genome can disrupt the biology of its host so
dramatically. Prophylactic vaccination and screening are
effective defenses to prevent a large fraction of HPV-
driven carcinomas. Viral detection and DNA methylation
analyses enable further stratification of infected patients at
high risk of progression to carcinoma. It is imperative that
molecular professionals choose analytic test strategies that
are in line with current evidence and that suit the needs of
their patient population. New diagnostic modalities, such
as massive parallel sequencing, have the power to revo-
lutionize HPV diagnostics and to identify changes in the
human genome, such as mutation signatures reflecting the
history of DNA damage and repair processes during clonal
evolution. Molecular pathologists are well positioned to
drive future improvements in test strategies to better guide
therapeutic interventions and to help prevent progression
of neoplasia.The Journal of Molecular Diagnostics - jmd.amjpathol.orgReferences
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